Dihydroergotamine: role in the treatment of migraine

Bibliography

• Silberstein SD. Migraine. Lancet 2004;363:381-91
   PubMed Web of Science ®Google Scholar
• Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006;5:148-57
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med 2005;118(Suppl 1):3S-10S
   PubMedGoogle Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
   PubMed Web of Science ®Google Scholar
• Evers S, May A, Fritsche G, et al. Akuttherapie und Prophylaxe der Migräne. Leitlinien der Deutschen Migräne- und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008;27:933-49
   Web of Science ®Google Scholar
• Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Current Treatment Options in Neurology. 2008;10:20-9
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 2008;28:877-86
   PubMed Web of Science ®Google Scholar
• Schiff PL. Ergot and its alkaloids. Am J Pharm Educ 2006;70:98
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-12
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
   PubMed Web of Science ®Google Scholar
• Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verh Schweiz Naturforsch Ges 1918;101:190-1
   Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43:144-66
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 1996;119(Pt 1):249-56
   PubMed Web of Science ®Google Scholar
• Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988;8:83-91
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11:165-8
   PubMed Web of Science ®Google Scholar
• Gröger D, Floss HG. Biochemistry of ergot alkaloids: achievements and challenges. In: Cordell GA, editor, The alkaloids. San Diego, Calif: Academic Press, Inc 1998. p. 172-218
   Google Scholar
• Cvak L. Industrial production of ergot alkaloids. In: Kren V, Cval L, editors, Ergot, the genus claviceps Medicinal and aromatic plants. Amsterdam, The Netherlands: Harwood Academic Publishers; 1999. p. 373-409
   Google Scholar
• Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (tempo) inhaler. Headache 2008;48:355-67
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62:509-25
   PubMed Web of Science ®Google Scholar
• Millan MJ, Marin P, Bockaert J, la Cour CM. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008;29:454-64
   PubMed Web of Science ®Google Scholar
• Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988;24:732-7
   PubMed Web of Science ®Google Scholar
• Villalon CM, Centurion D, Willems EW, et al. 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 2004;484:287-90
   PubMed Web of Science ®Google Scholar
• Hanoun N, Saurini F, Lanfumey L, et al. Dihydroergotamine and its metabolite, 8′-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain. Br J Pharmacol 2003;139:424-34
   PubMed Web of Science ®Google Scholar
• Schaerlinger B, Hickel P, Etienne N, et al. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol 2003;140:277-84
   PubMed Web of Science ®Google Scholar
• Humbert H, Cabiac MD, Dubray C, Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther 1996;60:265-75
   PubMed Web of Science ®Google Scholar
• Bobik A, Jennings G, Skews H, et al. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. Clin Pharmacol Ther 1981;30:673-9
   PubMed Web of Science ®Google Scholar
• Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982;13:785-90
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Clinical pharmacology of ergotamine. An overview. In: Diener HC, Wilkinson M, editors, Drug-induced headache. Berlin: Springer-Verlag; 1988. p. 105-16
   Google Scholar
• Müller-Schweinitzer E. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 1984;26:699-705
   PubMed Web of Science ®Google Scholar
• Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995-7
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334-9
   PubMed Web of Science ®Google Scholar
• Queiroz LP, Weeks RE, Rapoport AM, et al. Early and transient side effects of repetitive intravenous dihydroergotamine. Headache 1996;36:291-4
   PubMed Web of Science ®Google Scholar
• Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache 1993;33:471-5
   PubMed Web of Science ®Google Scholar
• Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med 1994;12:138-41
   PubMed Web of Science ®Google Scholar
• Weisz MA, el-Raheb M, Blumenthal HJ. Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache 1994;34:371-3
   PubMed Web of Science ®Google Scholar
• Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976-80
   PubMed Web of Science ®Google Scholar
• Becker WJ, Riess CM, Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996;36:144-8
   PubMed Web of Science ®Google Scholar
• Colman I, Brown MD, Innes GD, et al. Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med 2005;45:393-401
   PubMed Web of Science ®Google Scholar
• Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators. Headache 1995;35:177-84
   PubMed Web of Science ®Google Scholar
• Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285-91
   PubMed Web of Science ®Google Scholar
• Treves TA, Kuritzky A, Hering R, Korczyn AD. Dihydroergotamine nasal spray in the treatment of acute migraine. Headache 1998;38:614-7
   PubMed Web of Science ®Google Scholar
• Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia 1987;7:131-3
   PubMed Web of Science ®Google Scholar
• Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. [see comment]. Neurology 1994;44:447-53
   PubMed Web of Science ®Google Scholar
• Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361-5
   PubMed Web of Science ®Google Scholar
• Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 2000;54:281-6
   PubMed Web of Science ®Google Scholar
• Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49:826-37
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB, Kori SH, Miller SD, et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin 2008;24:1977-85
   PubMed Web of Science ®Google Scholar
• Bousser MG, Chick J, Fuseau E, et al. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. Cephalalgia 1988;8:187-92
   PubMed Web of Science ®Google Scholar
• Pradalier A, Lanteri-Minet M, Geraud G, et al. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs 2004;18:1149-63
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache 2006;46(Suppl 4):S212-20
   PubMed Web of Science ®Google Scholar
• Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-37
   PubMedGoogle Scholar
• Silberstein SD, Young WB, Hopkins MM, et al. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache 2007;47:878-85
   PubMed Web of Science ®Google Scholar
• Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Current Pain Headache Rep 2005;9:363-7
   PubMedGoogle Scholar
• Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache 1994;34:578-80
   PubMed Web of Science ®Google Scholar
• Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache 1997;37(Suppl 1):S33-41
   PubMed Web of Science ®Google Scholar
• Müller-Schweinitzer E, Weidmann H. Basic pharmacologic properties. In: Berde B, Schild HO, editors, Ergot alkaloids and related compounds. Berlin: Springer-Verlag; 1978. p. 87-232
   Google Scholar
• Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working panel of the headache and facial pain section of the American academy of neurology. [see comment]. Neurology 1995;45:577-84
   PubMed Web of Science ®Google Scholar
• Malaquin F, Urban T, Ostinelli J, et al. Pleural and retroperitoneal fibrosis from dihydroergotamine. N Engl J Med 1989;321:1760
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, editors, The headaches, 3 edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 459-67
   Google Scholar
• Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment fo migraine In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KMA, editors, The headaches, 3 edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. p. 469-502
   Google Scholar
• Katsarava Z, Holle D, Diener HC. Medication overuse headache. Curr Neurol Neurosci Rep 2009;9:115-9
   PubMed Web of Science ®Google Scholar
• Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Current Pain Headache Rep 2003;7:55-62
   PubMedGoogle Scholar